Eledon Pharmaceuticals Inc (ELDN)

$2.88 +0.14 (5.11%)
Market Cap 161.22M
Revenue (ttm) 0.00
Net Income (ttm) -36.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,660,700
Avg Vol 891,454
Day's Range N/A - N/A
Shares Out 59.93M
Stochastic %K 57%
Beta 0.84
Analysts Strong Sell
Price Target $8.00

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 238 8090
Website: eledon.com
Address:
19800 MacArthur Boulevard, Suite 250, Irvine, United States
FocusedGuidanceFocus
FocusedGuidanceFocus Mar. 18 at 5:49 AM
$ELDN appeared earlier, just keeping it in view.
0 · Reply
Smoore1212
Smoore1212 Mar. 17 at 11:15 PM
$ELDN $SANA gives hope to me as a father of a type 1. Invest early. This will happen
1 · Reply
TDMF123
TDMF123 Mar. 17 at 11:13 PM
$ELDN interesting price action tonight. Call holder still holding as of market close.
1 · Reply
ALRAE
ALRAE Mar. 17 at 10:45 PM
$ELDN 17+
0 · Reply
red1
red1 Mar. 17 at 8:39 PM
$ELDN 299% volume increase. Hoping for a 299% price increase
1 · Reply
Veraton
Veraton Mar. 17 at 8:23 PM
$ELDN priceless
0 · Reply
Veraton
Veraton Mar. 17 at 8:23 PM
$ELDN This is priceless
0 · Reply
cwork
cwork Mar. 17 at 8:02 PM
$ELDN https://www.linkedin.com/posts/breakthrought1d_exciting-university-of-chicago-clinical-trial-activity-7439747593582243841-8Jsn?utm_source=share&utm_medium=member_ios&rcm=ACoAABGRfDYB4I-QF0S1yZOvPboukTZSNWfjd9c
0 · Reply
Inbston1
Inbston1 Mar. 17 at 6:46 PM
$ELDN This stock will fly once the scientific and medical community notices the breakthrough of diabetes. Potential buyout candidate.
0 · Reply
KylaGPS10x
KylaGPS10x Mar. 17 at 5:22 PM
$ELDN thus will get noticed soon be prepared
0 · Reply
Latest News on ELDN
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative

Mar 16, 2026, 1:47 PM EDT - 1 day ago

Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

Mar 10, 2026, 7:00 AM EDT - 7 days ago

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Mar 9, 2026, 7:00 AM EDT - 8 days ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NCEL

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Mar 4, 2026, 4:05 PM EST - 13 days ago

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 4:10 PM EST - 5 weeks ago

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 23, 2026, 7:00 AM EST - 7 weeks ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Jan 8, 2026, 4:05 PM EST - 2 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 3 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Nov 18, 2025, 4:05 PM EST - 4 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 17, 2025, 1:07 PM EST - 4 months ago

Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 14, 2025, 5:00 PM EST - 4 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 7:56 AM EST - 4 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 11, 2025, 5:26 PM EST - 4 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Nov 7, 2025, 2:36 PM EST - 4 months ago

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Nov 7, 2025, 1:36 PM EST - 4 months ago

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 6, 2025, 6:30 PM EST - 4 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 4 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Oct 17, 2025, 7:00 AM EDT - 5 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Sep 24, 2025, 4:05 PM EDT - 6 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:00 AM EDT - 7 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 14, 2025, 4:20 PM EDT - 7 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Aug 6, 2025, 4:01 PM EDT - 7 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 8 months ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Jun 25, 2025, 4:01 PM EDT - 9 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025, 4:01 PM EDT - 10 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

May 6, 2025, 1:15 PM EDT - 11 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

May 3, 2025, 8:15 AM EDT - 11 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 28, 2025, 11:27 AM EST - 1 year ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 3:51 PM EDT - 1 year ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:30 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 9, 2024, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

May 7, 2024, 7:05 AM EDT - 2 years ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2024, 7:01 PM EST - 2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FocusedGuidanceFocus
FocusedGuidanceFocus Mar. 18 at 5:49 AM
$ELDN appeared earlier, just keeping it in view.
0 · Reply
Smoore1212
Smoore1212 Mar. 17 at 11:15 PM
$ELDN $SANA gives hope to me as a father of a type 1. Invest early. This will happen
1 · Reply
TDMF123
TDMF123 Mar. 17 at 11:13 PM
$ELDN interesting price action tonight. Call holder still holding as of market close.
1 · Reply
ALRAE
ALRAE Mar. 17 at 10:45 PM
$ELDN 17+
0 · Reply
red1
red1 Mar. 17 at 8:39 PM
$ELDN 299% volume increase. Hoping for a 299% price increase
1 · Reply
Veraton
Veraton Mar. 17 at 8:23 PM
$ELDN priceless
0 · Reply
Veraton
Veraton Mar. 17 at 8:23 PM
$ELDN This is priceless
0 · Reply
cwork
cwork Mar. 17 at 8:02 PM
$ELDN https://www.linkedin.com/posts/breakthrought1d_exciting-university-of-chicago-clinical-trial-activity-7439747593582243841-8Jsn?utm_source=share&utm_medium=member_ios&rcm=ACoAABGRfDYB4I-QF0S1yZOvPboukTZSNWfjd9c
0 · Reply
Inbston1
Inbston1 Mar. 17 at 6:46 PM
$ELDN This stock will fly once the scientific and medical community notices the breakthrough of diabetes. Potential buyout candidate.
0 · Reply
KylaGPS10x
KylaGPS10x Mar. 17 at 5:22 PM
$ELDN thus will get noticed soon be prepared
0 · Reply
red1
red1 Mar. 17 at 4:50 PM
$ELDN $VRTX https://youtu.be/FmNIT4rxXjg
0 · Reply
red1
red1 Mar. 17 at 3:12 PM
$ELDN volume 😮
0 · Reply
Veraton
Veraton Mar. 17 at 11:39 AM
$ELDN 🪽 Flying 🪽 Let's go for the big announcement!!!
1 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss Mar. 17 at 6:40 AM
$ELDN now all the flippers turning on a dime, till this drops 5 cents again. Then back at whining many times a day on this board about made up stuff.
0 · Reply
Veraton
Veraton Mar. 16 at 9:38 PM
$ELDN what's happening Thursday? Calls are still holding???
2 · Reply
red1
red1 Mar. 16 at 9:08 PM
$ELDN let’s see Thursday morning 😮
0 · Reply
Ontherag
Ontherag Mar. 16 at 8:48 PM
$ELDN Lookin good!
0 · Reply
cwork
cwork Mar. 16 at 8:16 PM
$ELDN
0 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss Mar. 16 at 8:07 PM
$ELDN
1 · Reply
Veraton
Veraton Mar. 16 at 8:01 PM
$ELDN 250.000 shares last five seconds.... Trying to go under the radar... Know what you own ! Massive 🐂
1 · Reply
cwork
cwork Mar. 16 at 5:32 PM
$ELDN https://youtu.be/1YgQ3t7csCQ?si=jhpEXdNkQMgXpWeJ
0 · Reply
red1
red1 Mar. 16 at 5:12 PM
$ELDN they’ll need $200M to $400M before tego starts making them money. That’s the disconnect most ppl need n this board have ! The drug is fantastic. The financials are not!
1 · Reply